STOCK TITAN

Altimmune, Inc. - ALT STOCK NEWS

Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.

Altimmune, Inc. (Nasdaq: ALT) is a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapeutics and vaccines addressing critical public health and biodefense needs. Leveraging the unique properties of its proprietary platform technologies, Altimmune is adept at swiftly designing product candidates targeting a range of diseases, including respiratory conditions, chronic infections, and cancer.

Altimmune's advanced Densigen™ T-cell platform technology is specifically designed to guide the immune system's response against complex disease targets by focusing on multiple antigens simultaneously. Another key platform, RespirVec™, uses needle-free intranasal delivery for faster and broader immunity against pathogens compared to traditional vaccines.

The company is also heavily involved in addressing obesity and liver diseases through its innovative peptide therapeutics. The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist under development for obesity and non-alcoholic steatohepatitis (NASH). Pemvidutide has shown promising results in clinical trials, achieving significant weight loss and liver fat reduction. It has received Fast Track designation from the U.S. FDA for treating NASH, highlighting its potential to meet significant unmet medical needs.

Altimmune's pipeline also includes HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. However, the company has recently decided to cease further development on HepTcell based on Phase 2 trial findings.

Financially, Altimmune maintains a robust cash position, enabling it to advance its clinical programs. Recent financial results indicate a focused investment in research and development, ensuring continued progress in its pipeline.

Significant recent achievements include:

  • Positive top-line results from the 48-week MOMENTUM Phase 2 obesity trial of pemvidutide.
  • Ongoing Phase 2b IMPACT trial of pemvidutide in MASH with top-line results expected in Q1 2025.
  • Strong financial position with substantial cash reserves to support ongoing and future research activities.

Altimmune is poised at the forefront of developing transformative therapies for serious health conditions, potentially delivering significant advancements in patient care.

Rhea-AI Summary

Altimmune presented the results of its Phase 1 clinical trial for pemvidutide at the 2022 International Liver Congress, focusing on obesity and NASH treatment. The presentation, titled "Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat", was delivered by Dr. Stephen A. Harrison on June 25, 2022. The study displayed significant findings, earning a spot in the congress's Best of International Liver Congress. Additionally, Dr. Scott Harris will discuss study findings at a press conference on June 24, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.89%
Tags
-
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced its participation in two upcoming investor conferences in June 2022. The events include the Jefferies 2022 Global Healthcare Conference on June 10 at 10:00 am ET and the JMP Securities Life Sciences Conference on June 16 at 9:00 am ET, both held in New York. Interested investors can access the webcast via the company’s website. Altimmune develops novel therapeutics for obesity and liver diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.15%
Tags
conferences
-
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Samuel Klein will present at the 82nd American Diabetes Association Scientific Sessions from June 3-7, 2022, in New Orleans, LA. He will discuss the results of a Phase 1 clinical trial for pemvidutide, a dual receptor agonist targeting obesity and NASH. The presentation is scheduled for June 6, 2022, at 4:30 pm CDT, highlighting pemvidutide's potential for significant weight loss without dose adjustments. Altimmune is committed to developing innovative peptide-based therapies for metabolic and liver diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences clinical trial
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced that Dr. Scott Harris will present at the 5th Global NASH Congress in London on May 27, 2022. His presentation will focus on pemvidutide, a novel dual receptor agonist aimed at treating obesity and NASH. Dr. Harris will also moderate a panel on clinical endpoints in NASH trials. The event highlights Altimmune's commitment to developing innovative therapeutics in the weight loss and liver disease sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
conferences clinical trial
-
Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company (Nasdaq: ALT), announced its participation in two investor conferences in May 2022. The H.C. Wainwright Global Investment Conference is set for May 24 at 7:00 am Eastern Time, available via webcast. The B. Riley Securities Institutional Investor Conference will take place on May 26 at 1:00 pm Pacific Time, featuring an in-person fireside chat. Altimmune focuses on developing novel therapeutics for obesity and liver diseases, including its lead candidate, pemvidutide (ALT-801).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
conferences
-
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2022, showcasing ongoing clinical developments of pemvidutide, a dual receptor agonist for obesity. Notably, interim data from the Phase 2 MOMENTUM trial is expected in Q4 2022, with 10% weight loss observed after 12 weeks. However, revenue was minimal at $0.0 million, down from $0.8 million YoY, primarily due to halted projects. R&D expenses rose to $15.1 million, leading to a net loss of $19.4 million. The company holds $180 million in cash, offering a healthy runway for future trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.63%
Tags
Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company, will announce its first quarter 2022 financial results on May 12, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on developing peptide-based therapeutics for obesity and liver diseases, with its primary candidate being pemvidutide (ALT-801) for obesity and NASH treatment. Additionally, it is developing HepTcell™, aimed at treating chronic hepatitis B.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.21%
Tags
conferences earnings
-
Rhea-AI Summary

Altimmune, a clinical-stage biopharmaceutical company, announced the successful completion of enrollment in its 12-week Phase 1b trial of pemvidutide for non-alcoholic fatty liver disease (NAFLD) and the initiation of the 48-week Phase 2 MOMENTUM trial for obesity. The MOMENTUM trial aims to evaluate the safety and efficacy of pemvidutide, targeting approximately 320 non-diabetic subjects. Results from a prior Phase 1 trial indicated an average weight loss of 10.3%. Key data readouts are anticipated in Q3 and Q4 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
-
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q4 and the full year of 2021, revealing a strong cash position of $190.3 million as of December 31, 2021. The company anticipates significant clinical data readouts over the next year, particularly from the pemvidutide (ALT-801) program, which showed promising results in weight loss and lipid reduction. The enrollment for the Phase 1b trial is over 90% complete, with data expected in Q3 2022. Revenue for Q4 2021 was $3.3 million, up from $2.3 million in Q4 2020, contributing to a net loss of $23.9 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.24%
Tags
Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) will report its fourth quarter and full year 2021 financial results on March 15, 2022. The management will host a conference call at 8:30 AM ET to discuss these results and provide a business update. The company focuses on novel peptide-based therapeutics for obesity and liver diseases, with its lead candidate, pemvidutide (ALT-801), being developed for obesity and NASH. Additional developments include HepTcell™, an immunotherapeutic for chronic hepatitis B.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
conferences earnings

FAQ

What is the current stock price of Altimmune (ALT)?

The current stock price of Altimmune (ALT) is $8.25 as of December 20, 2024.

What is the market cap of Altimmune (ALT)?

The market cap of Altimmune (ALT) is approximately 593.2M.

What does Altimmune, Inc. specialize in?

Altimmune specializes in developing next-generation immunotherapeutics and vaccines for public health and biodefense needs, focusing on platforms like Densigen™ and RespirVec™.

What are the main products in Altimmune's pipeline?

Altimmune's main pipeline products include pemvidutide for obesity and NASH, and HepTcell™ for chronic hepatitis B.

What is pemvidutide?

Pemvidutide is a GLP-1/glucagon dual receptor agonist under development for treating obesity and non-alcoholic steatohepatitis (NASH).

Has pemvidutide received any regulatory designations?

Yes, the U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of NASH.

What is Densigen™ platform technology?

Densigen™ is a T-cell platform technology designed to direct immune responses against multiple disease targets simultaneously, particularly effective for chronic infections and cancer.

How does the RespirVec™ platform work?

RespirVec™ utilizes needle-free intranasal delivery to provide rapid and broad immunity against disease pathogens, offering a more convenient alternative to traditional vaccines.

What recent financial results has Altimmune reported?

Recent financial results show focused investment in R&D, with substantial cash reserves to support ongoing and future research activities.

What are the current clinical trials for pemvidutide?

Altimmune is conducting the Phase 2b IMPACT trial for pemvidutide in MASH, with top-line results expected in Q1 2025. The 48-week MOMENTUM Phase 2 obesity trial has already shown positive results.

What is the status of HepTcell™ development?

Altimmune has decided to cease further development of HepTcell™ based on findings from the Phase 2 trial.

Where can I find more information about Altimmune?

More information about Altimmune can be found on their official website at www.altimmune.com.

Altimmune, Inc.

Nasdaq:ALT

ALT Rankings

ALT Stock Data

593.18M
70.56M
0.79%
56.73%
32.11%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
GAITHERSBURG